The key catalyst to watch is the PRECISE-AD Phase 1b interim data readout in early Q3 2026. Until then, no material news is expected. Traders should monitor for any data disclosures during the June conferences, but the press release itself provides no actionable trading signal.
Price Chart
Executive Summary
ProMIS Neurosciences announced participation in five June 2026 investor conferences and reiterated its timeline for the PRECISE-AD Phase 1b trial: blinded 6-month interim data in early Q3 2026 and 12-month topline data in early 2027. The press release contains no new financial data, clinical results, or material corporate events — it is a routine conference participation announcement.
Key Facts
- ProMIS will present at the Jefferies Global Healthcare Conference on June 4, 2026.
- ProMIS will present at the Wolfe Research Virtual Alzheimer’s R&D Day on June 4, 2026.
- ProMIS expects to report blinded 6-month interim data from the PRECISE-AD Phase 1b trial in early Q3 2026.
- ProMIS expects 12-month topline data from the PRECISE-AD Phase 1b trial in early 2027.
- The PRECISE-AD Phase 1b trial in early Alzheimer's disease patients is fully enrolled.
- No financial results, guidance, or material agreements were disclosed.
Financial Impact
No financial impact disclosed; the press release is a routine conference participation announcement.
Risk Factors
- Phase 1b interim data may fail to show sufficient safety or biomarker signals, leading to stock decline.
- Conference presentations may not produce new material disclosures, resulting in no price movement.
- Cash runway may be insufficient to fund operations through 2027 if data delays occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $9.12 $9.15 | ▲ +0.33% | ▲ +0.75% | $9.68 (+6.14%) |
Oct 6, 2026 21d ago | Press Release | $9.21 $9.12 | ▼ −0.98% | ▼ −0.74% | $9.68 (+5.10%) |
Sep 1, 2026 8w ago | Press Release | $13.35 $13.98 | ▲ +4.68% | ▲ +4.24% | $9.68 (−27.49%) |
Jul 14, 2026 15w ago | Press Release | $13.66 $14.01 | ▲ +2.53% | ▲ +2.13% | $9.68 (−29.14%) |
May 28, 2026 21w ago | Press Release | $10.87 $10.81 | ▼ −0.55% | ▼ −0.79% | $9.68 (−10.95%) |
May 12, 2026 24w ago | 8-K | $10.49 $10.57 | ▲ +0.76% | ▲ +0.19% | $9.68 (−7.72%) |
Apr 3, 2026 29w ago | EFFECT | $10.96 $10.88 | ▲ +0.73% | ▲ +0.79% | $9.68 (+11.68%) |
Mar 25, 2026 30w ago | S-3 | $15.13 $14.74 | ▲ +2.58% | ▲ +0.90% | $9.68 (+36.02%) |
Mar 18, 2026 31w ago | S-3 | $18.21 $17.60 | ▲ +3.35% | ▲ +1.61% | $9.68 (+46.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers